EPS for Sarepta Therapeutics Inc (SRPT) Expected At $-0.88

October 13, 2017 - By test

 EPS for Sarepta Therapeutics Inc (SRPT) Expected At $ 0.88
Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.09, from 1.43 in 2017Q1. It increased, as 19 investors sold Sarepta Therapeutics Inc shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported.
Tekla Cap Management Lc invested in 511,600 shares or 0.64% of the stock. Ig Invest Mgmt Ltd holds 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 52,000 shares. Jabre Prtnrs stated it has 0.04% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Next Finance Group Inc Inc holds 1,200 shares or 0% of its portfolio. Credit Suisse Ag owns 90,259 shares for 0% of their portfolio. 34,229 are held by Barclays Public Limited Company. Rock Springs Limited Partnership owns 205,000 shares. The New York-based Hudson Bay Cap Lp has invested 0.16% in Sarepta Therapeutics Inc (NASDAQ:SRPT). 154,400 were reported by Quantitative Invest Llc. Smith Asset Management Gp Ltd Partnership invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Omni Prtn Llp has invested 0.18% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Sigma Planning holds 21,180 shares or 0.07% of its portfolio. Peddock Capital Ltd Co holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 54 shares. Creative Planning reported 107,100 shares stake. Blair William Il has 17,025 shares for 0% of their portfolio.

Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report $-0.88 EPS on October, 26.They anticipate $0.22 EPS change or 20.00 % from last quarter’s $-1.1 EPS. After having $-1.15 EPS previously, Sarepta Therapeutics Inc’s analysts see -23.48 % EPS growth. The stock increased 0.21% or $0.11 during the last trading session, reaching $51.28. About 1.51 million shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since October 13, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 26 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 19 have Buy rating, 1 Sell and 6 Hold. Therefore 73% are positive. Sarepta Therapeutics had 88 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, October 23 by Jefferies. On Friday, September 1 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm earned “Neutral” rating on Tuesday, September 1 by SunTrust. Morgan Stanley maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Wednesday, January 4. Morgan Stanley has “Equal-Weight” rating and $33 target. Morgan Stanley upgraded the shares of SRPT in report on Monday, October 2 to “Overweight” rating. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Outperform” rating by RBC Capital Markets on Wednesday, August 26. Needham maintained it with “Buy” rating and $26 target in Friday, July 22 report. The stock has “Buy” rating by RBC Capital Markets on Monday, October 2. The rating was maintained by TH Capital on Wednesday, August 26 with “Buy”. As per Wednesday, August 5, the company rating was maintained by Roth Capital.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “Sarepta: Uncertainties And Controversies Surround Its Trials” on September 28, 2017, also Seekingalpha.com with their article: “Sarepta Therapeutics’ (SRPT) CEO Doug Ingram on Baird 2017 Global Healthcare …” published on September 14, 2017, Marketwatch.com published: “Sarepta shares rise nearly 3% premarket after RBC sees ‘compelling’ argument …” on October 09, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Marketwatch.com and their article: “Sarepta Therapeutics shares surge 7.5% after Morgan Stanley upgrade” published on October 02, 2017 as well as Seekingalpha.com‘s news article titled: “Sarepta Therapeutics: Catalysts With Partnered Programs Loom” with publication date: October 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: